Get the Stockscreener App
105.25
4.45%
4.48
Celcuity Inc stock is traded at $105.25, with a volume of 1.24M.
It is up +4.45% in the last 24 hours and up +23.61% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$100.77
Open:
$102.895
24h Volume:
1.24M
Relative Volume:
1.13
Market Cap:
$4.87B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-39.27
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
-0.36%
1M Performance:
+23.61%
6M Performance:
+737.98%
1Y Performance:
+734.66%
1-Day Range:
$102.38
$112.64
1-Week Range:
$100.00
$112.64
52-Week Range:
$7.575
$112.64
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
105.25 | 4.66B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity (NASDAQ:CELC) Hits New 1-Year HighShould You Buy? - MarketBeat
Eventide Asset Management LLC Buys 123,774 Shares of Celcuity, Inc. $CELC - MarketBeat
Wells Fargo Initiates Coverage of Celcuity (CELC) with Overweight Recommendation - Nasdaq
Is CELC Stock Overpriced? - timothysykes.com
RH Posts Strong Q3 Sales, Joins Canopy Growth, Tilray Brands, Frequency Electronics And Other Big Stocks Moving Higher On Friday - Benzinga
Celcuity stock hits all-time high at 109.15 USD By Investing.com - Investing.com Canada
Celcuity stock hits all-time high at 109.15 USD - Investing.com
Wells Fargo Initiates Celcuity With Overweight Rating, $126 Price Target - marketscreener.com
Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank - Finviz
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
Director Cashes Out: Celcuity Stock Sale Revealed! - TipRanks
Richard Buller Sells 3,000 Shares of Celcuity (NASDAQ:CELC) Stock - MarketBeat
New Highs: How interest rate cuts could boost Celcuity Inc stockWeekly Trade Summary & Safe Entry Zone Identification - BỘ NỘI VỤ
Dir Furcht Acquires 250 Of Celcuity Inc [CELC] - TradingView
Earnings Update: Why Celcuity Inc. stock is trending among retail tradersJuly 2025 Breakouts & Safe Entry Trade Signal Reports - BỘ NỘI VỤ
(CELC) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Celcuity stock rallies on Phase III breast cancer trial progress - MSN
17,848 Shares in Celcuity, Inc. $CELC Purchased by M Holdings Securities Inc. - MarketBeat
Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Celcuity (CELC) Price Target Increased by 11.17% to 108.57 - Nasdaq
Dir Buller Files To Sell 3,000 Of Celcuity Inc [CELC] - TradingView
Celcuity (NASDAQ:CELC) Sets New 1-Year HighShould You Buy? - MarketBeat
Saturn V Capital Management LP Boosts Stock Position in Celcuity, Inc. $CELC - MarketBeat
Geode Capital Management LLC Sells 42,691 Shares of Celcuity, Inc. $CELC - MarketBeat
Could Celcuity Drain The Lifeline Of Tumor Growth With Gedatolisib's Comprehensive Approach? - RTTNews
Aug Reactions: Why Celcuity Inc stock is rated strong buyPortfolio Value Summary & Free Accurate Trade Setup Notifications - BỘ NỘI VỤ
Celcuity stock hits all-time high at 103.23 USD By Investing.com - Investing.com Canada
Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In - AOL.com
Is Celcuity Inc. stock a defensive play in 2025Weekly Trend Summary & Stock Portfolio Risk Management - Newser
3 Stocks You’ll Wish You Bought Before 2026 - Investing.com
Celcuity Director Cashes In on Stock Sale! - TipRanks
Celcuity (NASDAQ:CELC) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat
Aug Swings: Does Celcuity Inc stock trade at a discount to peersWeekly Stock Summary & Long-Term Investment Growth Plans - BỘ NỘI VỤ
Jefferies Maintains Celcuity (CELC) Buy Recommendation - MSN
Celcuity submits gedatolisib new drug application to the FDA - MSN
Is Celcuity Inc. stock a bargain at current levelsEarnings Growth Report & Real-Time Chart Breakout Alerts - Newser
Jefferies raises Celcuity stock price target to $134 on positive trial outlook By Investing.com - Investing.com South Africa
Jefferies raises Celcuity stock price target to $134 on positive trial outlook - Investing.com
Dir Buller Files To Sell 1,100 Of Celcuity Inc [CELC] - TradingView
Is Celcuity Inc a good long term investmentChart Pattern Recognition & Small Budget Capital Growth - earlytimes.in
How to Value Roto Pumps Limited Stock Using DCF AnalysisTechnical Resistance Breaks & Rapid Capital Growth - earlytimes.in
Virtus Investment Advisers LLC Has $100,000 Stock Position in Celcuity, Inc. $CELC - MarketBeat
Celcuity outlines $2.5B–$3B peak revenue potential for gedatolisib amid accelerated launch preparations - MSN
How FDA Real-Time Review for Gedatolisib Has Changed Celcuity’s (CELC) Investment Story - simplywall.st
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results - AOL.com
Celcuity (CELC): Assessing Valuation Following Recent Share Price Surge - Yahoo Finance
Celcuity: From Speculative Bet To Pre-Commercial Powerhouse (NASDAQ:CELC) - Seeking Alpha
Aug Intraday: Does Celcuity Inc. stock trade at a discount to peersPortfolio Gains Summary & Free Low Drawdown Momentum Trade Ideas - moha.gov.vn
(CELC) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
How Celcuity Inc. stock reacts to job market dataJuly 2025 Macro Moves & Free Community Consensus Stock Picks - BỘ NỘI VỤ
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):